Related Experiment Video
Updated: May 29, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
A Performance-Based Adaptation Index for Automated Insulin Delivery Systems.
Jenny L Diaz C1,2, Patricio Colmegna1,3, Elliot Pryor1
1Center for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA, USA.
The Performance-Based Adaptation Index (PAI) automatically adjusts automated insulin delivery (AID) aggressiveness using continuous glucose monitoring (CGM) data. This tool enhances glycemic control for individuals with type 1 diabetes.
Area of Science:
- Biomedical Engineering
- Endocrinology
- Diabetes Technology
Background:
- Automated insulin delivery (AID) systems require personalized tuning for optimal performance.
- Individual insulin needs vary, necessitating adaptive algorithms.
- Continuous glucose monitoring (CGM) provides key data for algorithm adjustment.
Purpose of the Study:
- To introduce the Performance-Based Adaptation Index (PAI) for automatic adjustment of AID system aggressiveness.
- To enable AID systems to adapt to individual user needs and varying glycemic conditions.
- To improve glycemic outcomes in type 1 diabetes management.
Main Methods:
- Developed PAI integrating hypoglycemia and hyperglycemia CGM metrics into a single index.
- Proposed two computation methods for PAI: time in range (TIR) and glycemic risk indices.
- Assessed PAI feasibility in-silico using the UVA/Padova Type 1 Diabetes Simulator with a model predictive control (MPC) algorithm.
Main Results:
- PAI adjustment significantly improved Time in Range (TIR) from 35.1% to 71.8% in a conservative scenario.
- PAI reduced hypoglycemia exposure (TBR from 2.6% to 1.4%) in an aggressive scenario.
- PAI demonstrated safe and effective automatic tuning of the UVA-MPC controller in simulations.
Conclusions:
- PAI enables automatic tuning of AID controllers for improved glycemic control.
- Simulations show PAI can achieve TIR >70% in various physiological states.
- Clinical validation is recommended to confirm in-silico findings.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Inhaled Medications

